文献速递甲状腺疾病

医生对甲状腺功能减退症疗法的选择:患者特征的影响

Physician Choice of Hypothyroidism Therapy: Influence of Patient Characteristics.
PubMed 文献 · Thyroid · 2018-01-01

2017年对美国甲状腺协会成员进行问卷调查,通过13个临床场景评估医生对甲减治疗方案的选择。

要点

  • 索引患者中98%医生继续LT4治疗。
  • 患者症状强烈增加替代疗法处方(OR=25.6)。
  • 年龄较大和合并症降低替代疗法可能性。

核心结论

  • 在特定情况下医生处方联合疗法的意愿明显增加。
  • 若当前处方模式包含非LT4疗法,亟需研究其获益与风险。

研究设计与样本

  • 2017年对美国甲状腺协会成员进行问卷调查,389名受访者中363名医生处方甲减治疗。
  • 治疗选项包括继续LT4、增加LT4、减少LT4剂量加LT3、当前LT4剂量加LT3、甲状腺提取物替代LT4、LT3替代LT4。
  • 采用重复测量逻辑回归分析。

主要发现

  • 索引患者中98%医生继续当前LT4治疗。
  • 年龄较大和合并症降低替代疗法处方可能性(P=0.0002和P<0.0001)。
  • 除无甲状腺状态、患者性别和体重指数外,其他特征在多变量分析中均显著增加替代疗法可能性(P<0.0001)。

关键数值与推荐

  • 索引患者中98%医生继续LT4治疗。
  • 年龄较大P=0.0002,合并症P<0.0001,均降低替代疗法可能性。
  • 其他特征(除无甲状腺状态、性别、BMI外)P<0.0001,增加替代疗法可能性。

临床怎么用

  • 临床决策中应考虑患者症状对处方替代疗法的影响。
  • 年龄较大和合并症患者可能更倾向于维持LT4治疗。

局限性

  • 调查方法学存在公认局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Most endocrinologists encounter patients who are dissatisfied with their current hypothyroidism therapy and request combination therapy with either liothyronine (LT3) or thyroid extract. METHODS: A survey of American Thyroid Association members was conducted in 2017. Respondents were presented with 13 scenarios describing patients with hypothyroidism and were asked to choose among six therapeutic options. The index patient was satisfied taking levothyroxine (LT4) therapy. Twelve variations introduced parameters that potentially provide reasons for considering combination therapy (presence of symptoms, low serum triiodothyronine concentration, documentation of deiodinase polymorphisms). Therapeutic options included (i) continuing LT4, (ii) increasing LT4, (iii) adding LT3 to a reduced LT4 dose, (iv) adding LT3 to the current LT4 dose, (v) replacing LT4 with thyroid extract, and (vi) replacing LT4 with LT3. Repeated-measures logistic regression analysis was performed to examine both the prescribing of LT4 (options i and ii) versus all other therapies and the choice of continuing LT4 (option i) versus either increasing LT4 (option ii), adding LT3 (options iii and iv), or replacing LT4 with thyroid extract or LT3 (options v and vi). RESULTS: Of the 389 survey respondents, 363 physicians prescribed therapy for hypothyroidism. For the index patient, 98% of physicians continued current LT4 therapy. However, as the patient scenario incorporated other patient characteristics, physicians opted to increase LT4 dose or prescribe other therapies. The tendency to prescribe alternative therapies was powerfully increased by patient symptoms (odds ratio = 25.6 [confidence interval 9-73], p < 0.0001). Older age and the presence of a comorbidity reduced the likelihood that an alternative therapy was prescribed (p = 0.0002 and <0.0001, respectively). All other characteristics, except athyreotic status, patient sex, and body mass index, significantly increased the likelihood that alternative therapies would be prescribed in multivariate analyses (p < 0.0001). CONCLUSIONS: Even with the acknowledged limitations of survey methodology, this analysis appears to show a marked increase in the willingness of physicians to prescribe combination therapy in specific circumstances. If current prescribing patterns do incorporate the use of therapies other than LT4, there is a critical need for more research into the benefits and risks of these therapies.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Jonklaas J, Tefera E, Shara N, et al. Physician Choice of Hypothyroidism Therapy: Influence of Patient Characteristics. Thyroid. 2018. PMID: 30289349. doi:10.1089/thy.2018.0325

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。